What does a payer want to see before approving survodutide?

The pharmacy is accredited and I have verified that on the accreditor register.

I am trying to do this correctly the first time rather than learn it by getting it wrong.

I have already made one mistake here that cost me a vial, so I am being deliberately careful.

What is the correct sequence, and where is the step that people usually skip?

In practice, model the cost across the whole route, including the parts that are not the drug: consultation fees, laboratory monitoring, shipping, and the tests you will pay for yourself.

Denials come in two flavours and it is worth identifying which you have. A criteria denial means the submission did not evidence something the criteria require, and it is fixed by supplying the evidence. A formulary exclusion means the plan does not cover the drug at any level for any indication, and no amount of clinical documentation changes it — the route there is a formulary exception request or an employer-level appeal.

503A versus 503B

Concretely, a beyond-use date for a compounded multi-dose preparation is set under USP chapter provisions on the basis of microbiological risk category and, where available, supporting stability data. In practice most beyond-use dates in this space are default values from the risk-category table rather than the output of a stability study, and the two should not be read as equivalent claims.

USP General Chapter <797> on sterile preparation compounding sets the microbiological risk categories and default beyond-use dates that most compounded beyond-use dating in this space derives from.

Verify accreditation on the accreditor’s register rather than on the pharmacy’s website. It takes a minute.

The salt-versus-base issue is worth understanding precisely because it is a genuine regulatory tell rather than a technicality.

What a payer wants in a prior authorisation is documentation mapped to their own written criteria, in their own terms: a diagnosis code, a documented body mass index or comorbidity meeting their threshold, a record of a supervised lifestyle intervention over their specified duration, and documentation of any step-therapy agent tried and its outcome. A clinical narrative that does not map onto those fields will be denied by someone who never reads the narrative.

Features of a defensible telehealth intake: a real history including contraindications and family history, a recorded weight and height rather than a self-attested figure, baseline laboratory work or a documented reason for its absence, a named prescriber you can identify and verify, a titration plan, and a mechanism for reporting adverse events that reaches a clinician. A checkbox intake that issues a prescription in four minutes has none of these.

External review of health-plan denials in the United States operates under the Affordable Care Act’s appeal provisions and, for employer self-funded plans, under ERISA; the practical significance is that an independent reviewer applies the plan’s own criteria without the plan’s involvement.

If the intake did not ask about contraindications, that tells you what kind of service it is.

The distinction that governs most of this is between a preparation made for an identified patient against a prescription and a preparation made in bulk for office stock, and the two sit under different statutory provisions with different testing obligations.

The salt-form point: the statutory pathway for compounding a copy of an approved drug during a shortage applies to the same active moiety as the approved product. A preparation described as a salt form — "semaglutide sodium", "semaglutide acetate" — is describing a different chemical entity from the approved base, and the description is usually there to construct an argument that it is not a copy. Whatever the legal merits, it means what is in the vial is not what was studied.

Twelve-month cost modelling, laid out: take the monthly product cost, add consultation or subscription fees, add laboratory monitoring at your chosen interval, add shipping, and then adjust the product cost for actual delivered content and dead-space loss. The route that looks cheapest per vial frequently is not cheapest per twelve months, because the fee structure and the monitoring dominate at lower product costs.

The statutory basis for the 503A/503B distinction is sections 503A and 503B of the US Federal Food, Drug, and Cosmetic Act as amended by the Drug Quality and Security Act of 2013, and the FDA’s guidance documents on each are the authoritative description of what is permitted.

Keep every document. The appeal you might need in six months is built from records you have to have kept now.

Specifically, a defensible telehealth encounter has identifiable features, and the absence of those features is the most useful signal available to a prospective patient.

The internal-then-external appeal path is worth pursuing further than most people do, because the external reviewer is not the plan. Internal appeals are adjudicated by the entity that issued the denial; external review is conducted by an independent organisation against the same criteria, and it overturns a non-trivial fraction of denials.

FDA drug shortage list status is published and is the operative fact for whether compounding a copy of an approved drug is permitted under the relevant statutory exemptions; the status changes, and the change has downstream consequences for supply.

Worth noting that regulatory status in this area has changed repeatedly over the past three years, so any answer including a date should be checked against the current position.

Model twelve months, not one. The fee structures are designed to be compared monthly.